Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
Ginkgo Bioworks Holdings, Inc. reports developments around cell engineering, autonomous laboratory infrastructure, and contract research services that make biological R&D more programmable. Its updates cover Ginkgo Cloud Lab, Datapoints and Solutions services, Reconfigurable Automation Carts, Catalyst automation software, and AI-enabled workflows for protein engineering, nucleic acid design, cell-free systems, and biological manufacturing.
Company news also includes financial-results presentations, customer and research collaborations, agricultural biotechnology manufacturing work, and capital or governance updates. Following the completed divestiture of its Biosecurity business, recurring coverage centers on Ginkgo's autonomous lab strategy, remote wet-lab access, microbial strain engineering, fermentation processes, and the commercial use of lab-generated biological data.
Ginkgo Bioworks (NYSE: DNA) will host a third-quarter 2025 results presentation and live Q&A on Thursday, November 6, 2025 beginning at 4:30 p.m. ET. The presentation will review business performance for the quarter ended September 30, 2025.
Webcast details and the replay will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com. Investors can submit questions in advance via X using hashtag #GinkgoResults or by emailing investors@ginkgobioworks.com.
Ginkgo Bioworks (NYSE: DNA) announced a collaboration with STRM.BIO and the University of British Columbia under ARPA-H's EMBODY program to develop in vivo CAR therapies for autoimmune diseases on Oct 23, 2025.
The project, INVITE-ME, will combine STRM.BIO's megakaryocyte-derived extracellular vesicle delivery platform with Ginkgo's RNA construct design, nucleic acid AI, and immune cell engineering to pursue long-lived, tissue-specific CAR expression that could selectively eliminate autoreactive B and T cells without ex vivo manipulation.
Ginkgo Bioworks (NYSE: DNA) has announced new AI initiatives through its Datapoints offering to accelerate biologics drug discovery. The company launched two major programs: a strategic partnership with Apheris to create the Antibody Developability Consortium, and the AbDev AI Competition.
The Consortium aims to tackle biologics development challenges by combining Ginkgo's AI/ML capabilities with Apheris's federated computing infrastructure, allowing secure collaboration while maintaining data ownership. Initial datasets and models for multiple antibody formats are expected in 2026.
The AbDev AI Competition, running until early November with $60,000 in prizes, will establish standards for antibody developability modeling and identify areas needing improvement in the field.
Ginkgo Bioworks (NYSE: DNA) announced the settlement of shareholder derivative actions in the Northern District of California. The settlement includes a $4.125 million payment to be made by Individual Defendants' Insurers to Ginkgo within 30 days after Court judgment. The agreement includes $2.75 million in attorneys' fees and expenses, including $2,000 service awards to plaintiffs.
The settlement requires Ginkgo to terminate a specific contract and implement comprehensive corporate governance reforms for at least three years. The company's Board has determined the settlement terms are fair and in the best interests of Ginkgo and its stockholders. The Settlement Hearing is scheduled for December 18, 2025, where the Court will review the settlement's fairness and approve related fees.
Ginkgo Bioworks (NYSE: DNA) has announced a strategic partnership with Inductive Bio and Tangible Scientific to revolutionize AI-driven drug discovery workflows. The collaboration integrates three key capabilities: Ginkgo Datapoints' ADME profiling, Inductive Bio's chemistry design platform, and Tangible Scientific's compound management system.
The partnership aims to streamline the drug discovery process by combining high-throughput experimental workflows, compound management, and AI models into a unified service. Located in Boston's biopharma hub, the integrated platform offers rapid ADME profiling services including microsomal stability, kinetic solubility, P450 inhibition, and permeability testing, with optional in vitro toxicity assessments.
This collaboration supports the FDA's initiatives for faster development timelines, onshored services, increased AI tool usage, and adoption of non-animal preclinical testing approaches. The services are currently available for pharmaceutical and biotech teams.
Ginkgo Bioworks (NYSE: DNA) has appointed Brian O'Sullivan as Head of Commercial for Ginkgo Automation to accelerate external growth. O'Sullivan, formerly from HighRes Biosolutions, will oversee all revenue-generating functions including sales, business development, and marketing.
The appointment comes as Ginkgo Automation expands from internal R&D support to serving external clients with its RAC (Reconfigurable Automation Cart) hardware, Catalyst scheduling software, and remote monitoring services. O'Sullivan brings extensive experience in commercial leadership, having successfully grown HighRes's operations globally and held senior positions at Agilent Technologies, Velocity11, and Beckman Coulter.
Ginkgo Bioworks (NYSE: DNA) reported Q2 2025 financial results, with total revenue of $50 million, down from $56 million year-over-year. The company's Cell Engineering revenue grew 8% to $39 million, while Biosecurity revenue declined to $10 million. The company reported a GAAP net loss of $60 million, significantly improved from a $217 million loss in the prior year.
Notably, Ginkgo achieved its $250 million annualized cost reduction target three months ahead of schedule through workforce reductions and site consolidation. The company maintains its 2025 outlook of $167-$187 million in total revenue and aims to reach Adjusted EBITDA breakeven by the end of 2026. Ginkgo also expanded its services, launching new automated ADME profiling and cell-free protein synthesis systems.
Ginkgo Bioworks (NYSE: DNA), a leader in cell programming and biosecurity, has scheduled its Q2 2025 earnings presentation for Thursday, August 7, 2025, at 5:30 p.m. ET. The company will review its business performance for the quarter ended June 30, 2025.
Investors can access the presentation and Q&A session through Ginkgo's investor relations website. Questions can be submitted in advance via X (using #GinkgoResults) or email to investors@ginkgobioworks.com.
Ginkgo Bioworks (NYSE: DNA) has secured a $4.66M contract to deploy its Reconfigurable Automation Carts (RACs) technology at the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Laboratory. The project involves constructing a fully integrated workcell with 18 different devices within a modular anaerobic chamber.
The automation platform will enable remote operation of complex anaerobic phenotyping workflows, streamlining research processes for EMSL scientists. The system features a web-based software stack with API gateway access, supporting AI-driven autonomous science capabilities. The platform is expected to be fully operational later this year, advancing research in microbial engineering and biodesign.
Ginkgo Bioworks (NYSE: DNA) has launched a new high-throughput ADME profiling service through Ginkgo Datapoints, leveraging its proprietary RAC automation technology. The service aims to accelerate small molecule drug discovery by providing cost-competitive ADME testing within the United States, matching or beating prices from international vendors, including Chinese competitors.
The service features automated workflows, rapid turnaround times, and AI-compatible datasets designed to help researchers prioritize drug candidates more efficiently. This initiative demonstrates Ginkgo's commitment to delivering affordable, high-quality services to the biopharma industry while keeping operations U.S.-based.